25 of the Best Hematologist Oncologists Near Me

I enjoy advancing medicine through academics and excellent patient care.My particular interests are in clinical trial development and laboratory research investigating new agents to improve outcomes in patients with GI cancers. Dr. Scott is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Lynch Syndrome, Stomach Cancer, and Bone Marrow Aspiration. Dr. Scott is board certified in American Board Of Internal Medicine/Medical Oncology and American Board Of Internal Medicine. Dr. Scott is currently accepting new patients.

As a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins, my focus is on the various aspects of cellular therapy in the treatment of hematological malignancies. My primary research focus is to develop strategies to prevent relapse of hematological malignancies following allogeneic stem cell transplantation. Additionally, I serve as the director of the adult CAR T program for hematological malignancies as we grow our CAR T program to help patients with advanced hematological malignancies. My academic interest in this space lies in studying the aspects of toxicity of CAR T cell therapy with an aim to improve long term outcomes in these patients. Among hematological malignancies, myeloproliferative disorders are my area of interest and I work to study newer drugs in early phase of development and also its treatment using allogeneic stem cell transplantation. Patient appointments: 410-955-8893. Dr. Jain is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Splenectomy. Dr. Jain is board certified in American Board Of Internal Medicine.

Usama Gergis is an Oncologist and a Transplant Surgeon practicing medicine in Philadelphia, Pennsylvania. Dr. Gergis is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Graft. Dr. Gergis is board certified in Hematology. Dr. Gergis is currently accepting new patients.

Denise Levitan is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Levitan is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Cervical Cancer, Breast Cancer, and Myelodysplastic Syndrome (MDS). Dr. Levitan is board certified in American Board Of Internal Medicine, Medical Oncology.

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer. Dr. Tolaney is board certified in Medical Oncology.

Roger Stupp is a Hematologist Oncology specialist and a Neurologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 39 years. Dr. Stupp is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri.

Jacob Laubach is an Oncologist and a Hematologist practicing medicine in Boston, Massachusetts. Dr. Laubach is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Laubach is board certified in Hematology, Internal Medicine, and Medical Oncology.

Evan Alley is a Hematologist Oncology provider practicing medicine in Stuart, Florida. Dr. Alley is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Mesothelioma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Metastatic Pleural Tumor. Dr. Alley is board certified in American Board Of Internal Medicine, 2002.

Sagar Lonial is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 33 years. Dr. Lonial is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Aplastic Anemia, and Bone Marrow Transplant. Dr. Lonial is board certified in American Board Of Internal Medicine, 2000.

Jonathan Kaufman is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 27 years. Dr. Kaufman is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Primary Amyloidosis, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kaufman is board certified in American Board Of Internal Medicine, 2005.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Pancreatic Cancer. Dr. Sharfman is board certified in American Board Of Internal Medicine.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma. Dr. Hann is board certified in American Board Of Internal Medicine.

David Mcdermott is an Internal Medicine specialist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Mcdermott is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Melanoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy. Dr. Mcdermott is board certified in American Board Of Internal Medicine.

Aziz Nazha is a Hematologist and a Hematologist Oncology provider practicing medicine in Cherry Hill, New Jersey. Dr. Nazha is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Nazha is board certified in Medical Oncology and Hematology/Oncology. Dr. Nazha is currently accepting new patients.

Peter Silberstein is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. Dr. Silberstein is highly rated in 115 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Hodgkin Lymphoma, Clear Cell Sarcoma, Thyroidectomy, and Prostatectomy. Dr. Silberstein is board certified in Hematology - American Board Of Internal Medicine, Internal Medicine - American Board Of Internal Medicine, and Medical Oncology - American Board Of Internal Medicine. Dr. Silberstein is currently accepting new patients.

Cara Bondly is a Hematologist practicing medicine in Birmingham, Alabama. Dr. Bondly is highly rated in 265 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Childhood Iron Deficiency Anemia, Angiosarcoma, and Bone Marrow Aspiration.

Prasad Kudalkar is a Hematologist Oncology specialist and an Oncologist practicing medicine in Fairfield, Ohio. Dr. Kudalkar is highly rated in 115 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Lymphofollicular Hyperplasia. Dr. Kudalkar is board certified in American Board Of Internal Medicine. Dr. Kudalkar is currently accepting new patients.

Peter Voorhees is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Voorhees is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Voorhees is board certified in American Board Of Internal Medicine, Hematology. Dr. Voorhees is currently accepting new patients.

Adam M. Brufsky, MD, PhD, FACP, is professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine's Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women's Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; associate director for clinical investigations at UPMC Hillman Cancer Center; and codirector of the Comprehensive Breast Cancer Center.Dr. Brufsky is board-certified in internal medicine and medical oncology. He earned a medical and doctor of philosophy degrees from the University of Connecticut School of Medicine in Farmington, Conn.; completed a residency at Brigham and Women's Hospital, Harvard Medical School, and a fellowship at Dana-Farber Cancer Institute.Dr. Brufsky is a member of professional organizations, such as American Medical Association, Massachusetts Medical Society, American College of Physicians, American Society of Clinical Oncology, American Association for Cancer Research, Allegheny County Medical Society, Pennsylvania Medical Society, and Pennsylvania Oncologic Society. An active researcher, Dr. Brufsky has numerous abstracts and research articles in leading journals, and is principal investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army - Breast Cancer Research Program. Dr. Brufsky is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Gastrostomy. Dr. Brufsky is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Brufsky is currently accepting new patients.

Dr. Partridge received her MD from Cornell University Medical College in 1995. She completed her residency in internal medicine at the Hospital of the University of Pennsylvania and went on to complete fellowships in medical oncology and hematology at DFCI, MGH and BWH. She also received an MPH from Harvard School of Public Health. She is a medical oncologist who cares for adults with breast cancer, with a particular focus on the unique needs of young patients with breast cancer. She also leads efforts to optimize cancer survivorship care and research at DFCI. She completed fellowships in Medical Oncology and Hematology at DFCI, Massachusetts General Hospital and Brigham and Women’s Hospital. Dr. Partridge is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, BRCA Positive Breast Cancer, Hormone Replacement Therapy (HRT), and Salpingo-Oophorectomy. Dr. Partridge is board certified in Medical Oncology.

Veena John, MD, is the System Head for GYN/Medical Oncology for the Northwell Health Cancer Institute and an Assistant Professor of Medicine in the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Board certified in Internal Medicine, Hematology and Medical Oncology, she maintains an active practice caring for patients with gynecologic cancers where she focuses on providing compassionate, personalized, evidence-based multi-disciplinary care. In conjunction with physicians in Surgical Oncology, she pioneered a multi-disciplinary team approach for gynecologic oncology patients at the R.J. Zuckerberg Cancer Center where her practice is based. Dr. John is a highly experienced principal investigator for industry sponsored Phase I, II and III clinical trials in gynecologic oncology. She is the site principal investigator for the NRG cooperative group for the Northwell Health Cancer Institute and co-chair of the protocol review monitoring committee. Dr. John earned her medical degree from Christian Medical College in India, where she also completed her internal medicine internship. She completed her internal medicine residency at Flushing Medical Center and fellowship in hematology and medical oncology at North Shore University Hospital. She is an active member of the Society for Gynecologic Oncology, Society for Immunotherapy in Cancer, American Society of Clinical Oncology and American Society of Hematology as well as a member of the Ovarian Cancer committee for the national Gynecologic Oncology Group. Dr. John is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Testicular Yolk Sac Tumor, and Malignant Mixed Mullerian Tumor. Dr. John is board certified in American Board Of Internal Medicine, American Board Of Internal Medicine/Hematology, and American Board Of Internal Medicine/Medical Oncology.

I am a medical oncologist who specializes in the treatment of patients with skin cancer. I am part of a team of surgical oncologists, dermatologists, and radiation oncologists who all work together to determine the best treatment approach for each patient. My focus is on treating patients with advanced melanoma, as well as melanoma that is at high risk for recurrence after surgery. We also treat patients with merkel cell carcinoma and advanced basal cell and cutaneous squamous cell carcinoma. We also have a number of clinical trial options available, allowing our patients access to the newest therapies available. Dr. Salama is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Melanoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Primitive Neuroectodermal Tumor (PNET).

Diwakar Davar, MBBS, M.Sc is an assistant professor of medicine and a medical oncologist/hematologist. He specializes in the management of advanced melanoma and the development of early phase studies to test novel immunotherapeutic approaches to treat advanced cancers.;. Dr. Davar is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Metastatic Uveal Melanoma, Uveal Melanoma, and Gamma Knife Radiosurgery. Dr. Davar is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Davar is currently accepting new patients.

Gulam Manji, M.D., Ph.D. is an Associate Professor of Medicine at Columbia University Medical Center. Dr. Manji received his M.D. degree from Ross University School of Medicine in 2009 and completed his residency in internal medicine at Albany Medical College. He then completed his fellowship in Hematology/Oncology at NewYork-Presbyterian/Columbia, where his clinical focus was on the treatment of gastrointestinal malignancies, melanoma, and sarcoma under the mentorship of Dr. Gary Schwartz, Chief of Hematology and Oncology.Dr. Manji conducts translational research with the overall goal to developing new treatments for cancer. His focus is in gastrointestinal malignancies, particularly pancreas adenocarcinoma, on which he is conducting preclinical combination immunotherapy studies on genetically engineered mice with pancreas cancer in the Olive laboratory at the Herbert Irving Comprehensive Cancer Center. The combination immunotherapy preclinical proposal received the Young Investigator Award from the American Society of Clinical Oncology-2015. The goal of these preclinical studies is to bring promising new therapies to the clinic in an early phase clinical trials Dr. Manji's research career in identifying new genes and their implication in disease has led to numerous key publications and an issued patent.Dr. Manji cares for patients with gastrointestinal malignancies, with a particular focus on pancreatic and liver cancers, and sarcomas. He is the principal investigator of an investigator-initiated multicenter clinical trial that he wrote with Dr. Gary Schwartz in sarcoma and malignant peripheral nerve sheath tumors and is responsible for clinical trials conducted in liver, bile duct, gallbladder, and pancreas cancers at Columbia University Medical Center. Dr. Manji is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Malignant Peripheral Nerve Sheath Tumor, Splenectomy, and Pancreatectomy. Dr. Manji is board certified in Internal Medicine and Medical Oncology. Dr. Manji is currently accepting new patients.